ReviewFrontiers in oncology2026
Patient-derived prostate cancer organoids: model development, therapeutic applications, and challenges for precision oncology.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer ranks among the most prevalent male malignancies worldwide, with castration-resistant prostate cancer (CRPC) and drug resistance representing major clinical challenges. Conventional preclinical models fail to faithfully recapitulate tumor heterogeneity and the tumor microenvironment (TME). Patient-derived prostate cancer organoids (PCOs) represent a promising 3D model that largely preserves the genomic, phenotypic, and functional signatures of primary tumors. Building on prior studies that mostly focus on fragmented analyses and lack in-depth systematic integration, this narrative review attempts to establish a refined multidimensional research framework centered on "model optimization-mechanism exploration-clinical translation". Notably, it underscores the unique advantages of engineered PCOs and heterotypic co-culture organoid systems in resolving key clinical bottlenecks, particularly lineage transformation-driven therapeutic resistance and patient-specific TME heterogeneity. This study systematically elaborates the establishment methodologies of PCOs, critically evaluates the strengths, limitations, and iterative optimization strategies of diverse culture systems, and summarizes the core applications of PCOs in exploring tumor cellular origin, capturing tumor heterogeneity, modeling TME interactions, screening drug sensitivity, investigating resistance mechanisms, and advancing precision medicine for prostate cancer. Although PCO-based platforms still possess inherent limitations, including low establishment efficiency, rigorous culture requirements, and incomplete TME reconstruction, they harbor substantial translational potential. Furthermore, this review proposes targeted optimization strategies based on bioengineering and synthetic biomaterials, prospects the clinical translation of standardized PCO systems, and discusses existing research contradictions and unaddressed gaps in this field, aiming to provide a comprehensive, critical and novel theoretical reference for further basic research and clinical application of PCOs in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.